F18.250 Inhalant dependence with inhalant-induced psychotic disorder with delusions

Name of the Condition

• Common Name: Inhalant Dependence with Inhalant-Induced Psychotic Disorder with Delusions
• Medical Term: Inhalant Dependence with Inhalant-Induced Psychotic Disorder with Delusions

Summary

Inhalant dependence with inhalant-induced psychotic disorder with delusions is a substance use disorder characterized by a problematic pattern of inhalant use leading to clinically significant impairment or distress, accompanied by psychotic symptoms directly resulting from inhalant use. This condition involves a combination of physiological, behavioral, and cognitive symptoms related to continued use despite adverse consequences, including tolerance, withdrawal, and compulsive use, with the added complexity of psychotic features such as delusions.

Causes

Inhalant dependence with inhalant-induced psychotic disorder with delusions develops from repeated misuse of inhalants—substances that produce chemical vapors—for their psychoactive effects. Inhalants are often common household or industrial products, such as glue, paint thinners, aerosols, or solvents. Prolonged use can alter brain chemistry, leading to dependence and, in some cases, psychotic symptoms due to neurotoxic effects on the central nervous system.

Risk Factors

• Adolescents and young adults are more likely to experiment with inhalants.
• Individuals with a history of substance abuse or mental health disorders.
• Accessibility to inhalant products.
• Lack of proper supervision or guidance.

Symptoms

• Intense cravings or compulsive inhalant use.
• Coordination problems, dizziness, or lethargy.
• Unexplained behavioral changes such as aggression or mood swings.
• Cognitive impairment or memory issues.
• Withdrawal symptoms when use is reduced or stopped.
• Delusions (fixed false beliefs) directly related to inhalant use.
• Hallucinations or other psychotic symptoms.

Diagnosis

Diagnosis involves a comprehensive evaluation of the patient's history, including patterns of inhalant use, behavioral changes, and psychotic symptoms. Clinicians assess for dependence criteria, such as tolerance, withdrawal, and continued use despite harm. Psychotic symptoms must be directly attributable to inhalant use, not due to another medical or psychiatric condition. Laboratory tests or imaging may be used to rule out other causes, and a detailed psychiatric assessment is essential to confirm the diagnosis.

Treatment Options

Treatment typically includes a combination of medical and behavioral interventions. Medical management may address withdrawal symptoms and co-occurring conditions. Behavioral therapies, such as cognitive-behavioral therapy, help modify patterns of use and address underlying issues. Supportive care, including counseling and peer support, is often recommended. In some cases, medications may be used to manage psychotic symptoms or comorbidities, though inhalant-specific treatments are limited.

Prognosis and Follow-Up

Prognosis varies depending on the severity of dependence, duration of use, and response to treatment. Early intervention improves outcomes, but relapse is common. Long-term follow-up is necessary to monitor for recurrence of use or psychotic symptoms. Ongoing support and therapy are critical to maintaining recovery and addressing any residual effects.

Complications

• Worsening of psychotic symptoms, including persistent delusions.
• Cognitive impairment or neurological damage.
• Respiratory or organ damage from prolonged inhalant use.
• Social or occupational dysfunction.
• Increased risk of accidents or injuries due to impaired judgment.

Lifestyle & Prevention

• Avoiding access to inhalant products, especially for at-risk individuals.
• Educating communities about the risks of inhalant misuse.
• Providing alternative coping strategies and support for stress or mental health issues.
• Encouraging open communication about substance use within families or support networks.

When to Seek Professional Help

Seek help if there are signs of inhalant dependence, such as compulsive use, withdrawal symptoms, or unexplained behavioral changes. Immediate medical attention is needed if psychotic symptoms, such as delusions or hallucinations, develop or worsen. Professional evaluation is critical to determine the appropriate level of care and intervention.

Tips for Medical Coders

When coding for F18.250, ensure documentation supports both inhalant dependence and the presence of inhalant-induced psychotic disorder with delusions. The psychotic symptoms must be directly linked to inhalant use, and the delusions should be clearly noted in the clinical record. Verify that the diagnosis aligns with the criteria for substance-induced psychotic disorder and that other causes of psychosis are ruled out. Accurate documentation of the relationship between inhalant use and psychotic symptoms is essential for proper coding.